RSV

Icosavax raises $51M to take VLP RSV vaccine into humans
Icosavax raises $51M to take VLP RSV vaccine into humans
Fierce Biotech
Icosavax
vaccines
RSV
VLP
viruslike particle
IVX-121
Flag link:
Meissa raises $30M to take RSV vaccine into the clinic
Meissa raises $30M to take RSV vaccine into the clinic
Fierce Biotech
Meissa Vaccines
vaccines
RSV
clinical trials
Flag link:
Enanta's lung infection therapy succeeds in mid-stage trial
Enanta's lung infection therapy succeeds in mid-stage trial
Reuters
Enanta Pharmaceuticals
RSV
clinical trials
EDP-938
Flag link:
Novavax still plans to push RSV vaccine to market after failed trial
Novavax still plans to push RSV vaccine to market after failed trial
Bizjournals
Novavax
RSV
clinical trials
vaccines
ResVax
Flag link:
J&J mops up $900M in waste, writing off the last big chunk of the $1.75B it spent to acquire Alios
J&J mops up $900M in waste, writing off the last big chunk of the $1.75B it spent to acquire Alios
Endpoints
JNJ
Alios
RSV
Flag link:
Can Novavax Convince the FDA Its Vaccine Deserves a Chance?
Can Novavax Convince the FDA Its Vaccine Deserves a Chance?
Motley Fool
Novavax
RSV
vaccines
FDA
clinical trials
Flag link:
Another PhIII RSV failure thumps beleaguered Novavax, but execs claim there's a way forward
Another PhIII RSV failure thumps beleaguered Novavax, but execs claim there's a way forward
Endpoints
RSV
vaccines
Novavax
clinical trials
Flag link:
AZ’s lung drug gets fast development in EU and US
AZ’s lung drug gets fast development in EU and US
Pharmaforum
AstraZeneca
MEDI8897
RSV
Europe
fast track
Flag link:
AstraZeneca makes $1B-plus in cash-and-stock deal granting Sobi US rights to RSV drug Synagis
AstraZeneca makes $1B-plus in cash-and-stock deal granting Sobi US rights to RSV drug Synagis
Endpoints
AstraZeneca
Sobi
Synagis
RSV
Flag link:
J&J takes $630M hit on RSV drug bought with Alios
J&J takes $630M hit on RSV drug bought with Alios
Fierce Biotech
JNJ
RSV
Alios BioPharma
AL-8176
lumicitabine
Flag link:
ReViral Completes $55 Million Series B Round to Advance RSV Treatment
ReViral Completes $55 Million Series B Round to Advance RSV Treatment
CP Wire
ReViral
RSV
RV521
Flag link:
Pfizer Begins a Phase 1/2 Study to Evaluate RSV Vaccine
Pfizer Begins a Phase 1/2 Study to Evaluate RSV Vaccine
CP Wire
Pfizer
vaccines
RSV
clinical trials
RSV Vaccine
Flag link:
Pfizer Begins a Phase 1/2 Study to Evaluate RSV Vaccine
Pfizer
RSV
RSV Vaccine
vaccines
Flag link:
Ph III Study of Infant via Maternal Immunization Vaccine for RSV Reaches Milestone
Ph III Study of Infant via Maternal Immunization Vaccine for RSV Reaches Milestone
CP Wire
Novavax
RSV
vaccines
RSV F vaccine
infant via maternal immunization
Flag link:
JPM18: Novavax investors cheer RSV vaccine update, then pull back
JPM18: Novavax investors cheer RSV vaccine update, then pull back
Biopharma Dive
Novavax
vaccines
RSV
JPMHC 2018
Flag link:
In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure
In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure
Endpoints
Regeneron
RSV
clinical trials
REGN2222
suptavumab
Flag link:
Novavax makes a case for a do-over on its failed RSV vaccine — but it’s an uphill climb
Novavax makes a case for a do-over on its failed RSV vaccine — but it’s an uphill climb
Endpoints
Novavax
vaccines
RSV
RSV F vaccine
Flag link:
Eyeing a $6B market, Bavarian Nordic posts positive phase 2 data for universal RSV vaccine
Eyeing a $6B market, Bavarian Nordic posts positive phase 2 data for universal RSV vaccine
Fierce Pharma
Bavarian Nordic
clinical trials
vaccines
RSV
Flag link:
Sanofi steps up with a $645M deal to partner with AstraZeneca on a late-stage RSV antibody
Sanofi steps up with a $645M deal to partner with AstraZeneca on a late-stage RSV antibody
Endpoints
Sanofi
AstraZeneca
RSV
MEDI8897
Flag link:
Novavax aims to rebound with restructuring, more trials
Novavax aims to rebound with restructuring, more trials
BioPharma Dive
Novavax
restructuring
clinical trials
RSV
Flag link:

Pages